By inserting a single LinQ allograft into the SI joint, physicians can ease or even remove chronic pain following a comprehensive diagnostic process. Credit: Marinesea / Shutterstock.
PainTEQ has received a new US patent for its LinQ SI Joint Stabilization System aimed at alleviating sacroiliac (SI) joint pain.
The No. 12,121,458 patent protects design features aimed at improving the efficiency and precision of the procedure, along with the safety of the patient.
The newly granted patent introduces two main advancements in instrument alignment. Claims one to six detail the joint locator usage with a keying protrusion for alignment with the cannula through a guidance slot.
Claims seven to 12 extend the scope by reversing the roles, placing the protrusion on the cannula while the joint locator is designed with a channel to receive it.
With this latest patent, the company’s intellectual property portfolio includes advancements in alignment tools. The patented technologies are designed to decrease outcome variability, safeguard safety with intuitive, single-use designs, and streamline surgical workflows.
The system offers a minimally invasive solution for individuals suffering from sacroiliac disease. By inserting a single LinQ allograft into the SI joint, physicians can ease or even remove chronic pain following a comprehensive diagnostic process.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
[View profiles in store](https://www.globaldata.com/companies/?utm_source=News&utm_term=visit_company_profile&utm_content=PainTEQ receives new US patent for SI joint system)
Company Profile – free sample
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Patented instrumentation and a large graft window of the system are designed to foster an optimal environment for long-term fusion, with an emphasis on efficiency and precision.
PainTEQ Marketing and R&D director Jeremy Carr said: “PainTEQ’s mission is to transform SI joint dysfunction treatment, and this new patent underscores our commitment to delivering cutting-edge solutions that prioritise patient well-being.
“By continually innovating and expanding the capabilities of our LinQ System, we are setting new standards industrywide and improving quality of life for countless individuals who suffer from SI joint pain.”
SI joints can become inflamed due to hypermobility, where the ligaments allow excessive movement, or hypomobility, often caused by arthritis, which restricts movement and leads to bones rubbing together. Both conditions can result in significant pain.
Email newsletter icon
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.